BackgroundTaxane. carboplatin and trastuzumab (TCH) is an effective neoadjuvant regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer with high pathologic complete response (pCR) rate. The KATHERINE trial changes the outlook for high-risk HER2-positive breast cancer. which suggests that escalation treatment for patients with residual disease after neoadjuv... https://www.getpureroutine.com/top-deal-chromasilk-7-35-7gm-golden-mahogany-blonde-online-sale-best-super/